Odulimomab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Odulimomab ?
Monoclonal antibody
Type Whole antibody
Source Mouse
Target CD11a
Clinical data
Legal status ?
Identifiers
CAS number 159445-64-4 N
ATC code None
Chemical data
Formula ?
 N (what is this?)  (verify)

Odulimomab is an investigational drug for the prevention of transplant rejection[1][2] and for the treatment of various immunological diseases.[3][4]

It is a mouse monoclonal antibody directed against the alpha chain of the protein lymphocyte function-associated antigen 1 which is involved in immune reactions.[1]

References[edit]

  1. ^ a b Martin, X; Da Silva, M; Virieux, SR; Hadj Aissa, A; Buffet, R; Tiollier, J; Dubernard, JM (2000). "Protective effect of an anti-LFA 1 monoclonal antibody (odulimomab) on renal damage due to ischemia and kidney autotransplantation". Transplantation proceedings 32 (2): 481. doi:10.1016/S0041-1345(00)00849-6. PMID 10715487. 
  2. ^ Crétolle-Vastel, C; Camby, C; Cerf-Bensussan, N; Cavazzana-Calvo, M; Fischer, A; Révillon, Y; Sarnacki, S (1999). "Role of calcineurin-dependent drugs on the immunosuppressive effect induced by the anti-LFA-1 antibody in a fetal intestinal transplantation model in mice". Chirurgie; memoires de l'Academie de chirurgie 124 (5): 503–10. PMID 10615777. 
  3. ^ Whitcup, SM; Chan, CC; Kozhich, AT; Magone, MT (1999). "Blocking ICAM-1 (CD54) and LFA-1 (CD11a) inhibits experimental allergic conjunctivitis". Clinical immunology (Orlando, Fla.) 93 (2): 107–13. doi:10.1006/clim.1999.4775. PMID 10527686. 
  4. ^ Corbascio, M; Mahanty, H; Osterholm, C; Qi, Z; Pearson, TC; Larsen, CP; Freise, CE; Ekberg, H (2002). "Anti-lymphocyte function-associated antigen-1 monoclonal antibody inhibits CD40 ligand-independent immune responses and prevents chronic vasculopathy in CD40 ligand-deficient mice". Transplantation 74 (1): 35–41. doi:10.1097/00007890-200207150-00007. PMID 12134096.